Bristol Myers Squibb warns UK medicines levy threatens investment
The chief executive of Bristol Myers Squibb has warned that the US pharmaceutical company could divert investment away from the UK due to the expansion of a levy designed to limit the NHS’s medicines bill.
Giovanni Caforio also said low pricing for medicines purchased by the NHS from pharmaceutical companies was a major issue that threatened the UK’s ambition to become a leader in the life sciences industry.
Caforio told the Financial Times he was “very concerned” by the voluntary scheme for branded medicines pricing and access in the UK.
This story originally appeared on: Financial Times - Author:Jamie Smyth
